Table 2 Recent (2010 to present) putative prognostic biomarkers of prostate cancer discovered using various mass spectrometry platforms

2D-PAGE + MALDI-TOF/TOF

Panel of 17 candidates

Tissue: Gleason score 5

(n = 4) compared with Gleason score 7 (n = 4)

Alaiya et al. [104]

Panel of 6 candidates

Tissue: localized (n = 7) compared with lymph node metastases (n = 1)

Pang et al. [105]

Lamin A

Tissue: low (n = 23) compared with

high (n = 23) Gleason

ROC AUC^a = 0.88

Skvortsov et al. [106]

Transthyretin

Serum: n = 4

Wang et al. [107]

Clusterin

Serum: n = 4

Wang et al. [107]

Shotgun proteomics

Panel of 5 markers

Tissue (n = unknown)

Drake et al. [108]

Panel of 3 markers

Pooled serum: metastases (n = 5) compared with progressing (n = 5)

Rehman et al. [109]

Panel of 7 candidates

Pooled serum: metastases (n = 5) compared with progressing (n = 5)

Rehman et al. [109]

Panel of 5 markers

Serum: Gleason <7 (n = 27) compared with ≤7 (n = 27)

ROC AUC^a = 0.79

Cima et al. [86]

Acetyl-coenzyme A acetyltransferase

Cell lines: androgen-dependent compared with androgen-independent

Saraon et al. [110]

Targeted proteomics

Alpha-methylacyl-CoA racemase

Pooled tissue: localized compared with metastases

Yocum et al. [111]

Enhancer of zeste homolog 2

Pooled tissue: localized compared with metastases

Yocum et al. [111]